<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396470</url>
  </required_header>
  <id_info>
    <org_study_id>55936</org_study_id>
    <nct_id>NCT04396470</nct_id>
  </id_info>
  <brief_title>tVNS in Children With Prader-Willi Syndrome</brief_title>
  <official_title>Transcutaneous Vagus Nerve Stimulation in Children With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current project is to test the impact of transcutaneous vagus nerve
      stimulation (tVNS) on social ability in children with Prader-Willi Syndrome (PWS). Social
      ability and blood neuropeptides associated with social functioning will be measured before
      and after engagement in 12 weeks of tVNS therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Social Responsiveness Scale, 2nd Edition (SRS-2)</measure>
    <time_frame>pre-post 12 week intervention period</time_frame>
    <description>Identifies the presence and severity of social impairments in child participants by parent report</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <condition>Social Behavior</condition>
  <arm_group>
    <arm_group_label>tVNS treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tVNS sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tVNS</intervention_name>
    <description>Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.</description>
    <arm_group_label>tVNS sham treatment</arm_group_label>
    <arm_group_label>tVNS treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) be between the ages of 8-14 years; (2) have a confirmed diagnosis of PWS by
             genetic testing; (3) be minimally verbal and able to sit at a table to complete
             cognitive and behavioral testing; (4) be willing to provide blood samples; and (5) be
             willing to engage in a 16-week study period (baseline to intervention follow-up).

        Exclusion Criteria:

          -  (1) currently taking oxyotocin and/or arginine vasopressin or related analogs and (2)
             have a DSM-5 diagnosis of any severe mental or behavioral disorder (e.g.
             schizophrenia, bipolar disorder, conduct or oppositional defiant disorder) that
             significantly impacts daily functioning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen J. Parker, PhD</last_name>
    <phone>(650) 736-9863</phone>
    <email>kjparker@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olena Zyga, PhD</last_name>
    <phone>(650) 498-5187</phone>
    <email>ozyga@stanford.edu</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Karen Parker</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

